NASDAQ| TSX: ACB
Canada's Largest Medical Cannabis Company to Participate as an Industry Leader in the Inaugural Regulatory Event in Washington, D.C.
EDMONTON, AB, March 25, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to be attending, sponsoring and speaking at the 2025 Global Cannabis Regulatory Summit (GCRS), held within the U.S. Capitol Complex in Washington, D.C. on March 26-27, 2025.
"The opportunity to speak on this global stage, underscores our position as industry leaders and demonstrates our ability to advocate for policy reform around the world," says Rick Savone, Senior Vice President of Global Government Relations at Aurora. "It is essential that we work together - across borders and sectors - to seize the opportunities that lie ahead for our industry. We are eager to engage with leaders from around the world as we continue to advance policies that drive resilient growth and positive change."
The GCRS, hosted by Artemis Growth Partners, will allow for regulators, members of Congress, international policy experts, and leading cannabis industry executives from around the world to come together and discuss the future of the global cannabis industry.
The panel discussions that Aurora will be participating in will foster a deepened understanding of the differences between medical and adult-use of cannabis based on international political and regulatory consensus. As well as discuss how jurisdictions with more mature medical cannabis programs can effectively inform regulations in emerging markets.
For more information about the GCRS, please visit: https://cannabisregsummit.com/
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's plans to participate at the 2025 GCRS Summit, the Company's position as an industry leader and its ability to advocate for policy reform around the world, and future opportunities for the Company and industry, including with respect to the advancement of policies that drive resilient growth and positive change.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
SOURCE Aurora Cannabis Inc.

For Media: Michelle Lefler | VP, Communications & PR | [email protected]
Share this article